ARCHIVES

Phase III Data of Antibody-Drug Conjugate Shows PFS Increase in HER2+ Disease

This article is from The Cancer Letter archive.

Vol. 35 No. 6 | June 29, 2012

Download PDF Visit The Full Archive

Related Articles

NCI Official Says Public Health Issue As Important As Data In Mammography

April 2, 1993

Survival Benefit For Vinorelbine-Cisplatin In NSCLC Patient, Phase III Trial Finds

August 26, 2005

Enzastaurin Shows Activity In Recurrent High-Grade Glioma

June 24, 2005

In Brief: Lombardi Comprehensive Designation Renewed; Yale Plans Breast Cancer Lab

September 26, 1997

ODAC Reviews Post-Marketing Studies for Eight Indications

March 21, 2003

NCI Finds Physician Recommendation Drives Patient Demand For ABMT

July 19, 1996